| Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients (NCT01611961) | Shenyang Pharmaceutical University | 2012-08-01 |
| Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood (NCT01543841) | University Health Network, Toronto | 2012-08-01 |
| A Study of LY3023414 in Participants With Advanced Cancer (NCT01655225) | Eli Lilly and Company | 2012-07-31 |
| Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients (NCT01576406) | Pfizer | 2012-07-01 |
| Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer (NCT01505153) | Gradalis, Inc. | 2012-02-01 |
| Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated (NCT02069067) | National Cancer Institute, Naples | 2011-12-01 |
| Cancer End Of Life Evaluation (NCT01545921) | Institut Cancerologie de l'Ouest | 2011-11-11 |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (NCT01744249) | Grupo Espanol de Tumores Neuroendocrinos | 2011-11-01 |
| Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer (NCT01660360) | PharmAbcine | 2011-11-01 |
| Family and Coping Oriented Palliative Homecare Nursing Aimed at Advanced Cancer Patients (NCT01444157) | Bispebjerg Hospital | 2011-10-01 |
| Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer (NCT01347866) | Pfizer | 2011-10-01 |
| An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer (NCT01443390) | Scottsdale Healthcare | 2011-09-01 |
| A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer (NCT01527331) | Massachusetts General Hospital | 2011-06-01 |
| Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (NCT01361607) | Jazz Pharmaceuticals | 2011-05-27 |
| A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (NCT01833923) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2011-05-01 |
| Emergency Department-Based Palliative Care for Advanced Cancer Patients (NCT01358110) | Icahn School of Medicine at Mount Sinai | 2011-05-01 |
| Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies (NCT01339871) | M.D. Anderson Cancer Center | 2011-04-20 |
| Paracetamol for Cancer Pain (NCT01313247) | Haraldsplass Deaconess Hospital | 2011-04-01 |
| Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) (NCT01295632) | Merck Sharp & Dohme LLC | 2011-02-01 |
| C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors (NCT01296568) | Eli Lilly and Company | 2011-02-01 |
| Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain (NCT01337089) | Jazz Pharmaceuticals | 2011-01-19 |
| Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies. (NCT02841124) | Centre Hospitalier Universitaire de Besancon | 2011-01-01 |
| The Role of the EKG in Anticancer Drug Development (NCT01462383) | M.D. Anderson Cancer Center | 2011-01-01 |
| Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies (NCT01463982) | Hanmi Pharmaceutical Company Limited | 2010-12-01 |
| A Phase 1 Study of LY2874455 in Participants With Advanced Cancer (NCT01212107) | Eli Lilly and Company | 2010-12-01 |
| Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer (NCT01262651) | GW Pharmaceuticals Ltd | 2010-11-25 |
| Intervention Study of Communication in Oncologist-Patient Encounters (NCT00994578) | Duke University | 2010-11-01 |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (NCT01197170) | M.D. Anderson Cancer Center | 2010-09-07 |
| Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer" (NCT01976910) | DEKK-TEC, Inc. | 2010-09-01 |
| Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer (NCT01048008) | DEKK-TEC, Inc. | 2010-09-01 |
| A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients (NCT01209832) | Eli Lilly and Company | 2010-09-01 |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (NCT01187199) | M.D. Anderson Cancer Center | 2010-08-19 |
| Temsirolimus In Phase 0 (NCT01417065) | M.D. Anderson Cancer Center | 2010-08-01 |
| A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma (NCT01185548) | Eli Lilly and Company | 2010-07-01 |
| Notch Inhibitor in Advanced Cancer (NCT01158404) | Eli Lilly and Company | 2010-07-01 |
| Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life (NCT01367795) | University Hospital, Basel, Switzerland | 2010-07-01 |
| Bendamustine and Bevacizumab for Advanced Cancers (NCT01152203) | M.D. Anderson Cancer Center | 2010-06-01 |
| FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib (NCT01143779) | M.D. Anderson Cancer Center | 2010-06-01 |
| Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies (NCT01113476) | M.D. Anderson Cancer Center | 2010-04-27 |
| A Study of LY2875358 in Participants With Advanced Cancer (NCT01287546) | Eli Lilly and Company | 2010-04-13 |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (NCT01087554) | M.D. Anderson Cancer Center | 2010-03-01 |
| Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer (NCT01539733) | Amsterdam UMC, location VUmc | 2010-03-01 |
| Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer (NCT01423903) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-02-01 |
| A Phase 1 Study in Participants With Advanced Cancer (NCT01115790) | Eli Lilly and Company | 2010-02-01 |
| A Dose-escalation Study in Subjects With Advanced Malignancies (NCT01072266) | Incyte Corporation | 2010-01-01 |
| Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer (NCT01887041) | Universitätsklinikum Hamburg-Eppendorf | 2010-01-01 |
| Docetaxel and Sirolimus in Patients With Advanced Malignancies (NCT01054313) | M.D. Anderson Cancer Center | 2010-01-01 |
| A Phase 1 Study of LY2835219 In Participants With Advanced Cancer (NCT01394016) | Eli Lilly and Company | 2009-12-07 |
| Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies (NCT01015222) | M.D. Anderson Cancer Center | 2009-11-01 |
| HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver (NCT00980239) | M.D. Anderson Cancer Center | 2009-09-01 |
| Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients (NCT00965341) | M.D. Anderson Cancer Center | 2009-09-01 |
| Using Video Images to Improve Advance Care Planning in Patients With Cancer (NCT00970125) | Massachusetts General Hospital | 2009-08-01 |
| Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials (NCT00949390) | M.D. Anderson Cancer Center | 2009-07-01 |
| Sirolimus and Cetuximab in Advanced Malignancies (NCT00940381) | M.D. Anderson Cancer Center | 2009-07-01 |
| Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study (NCT00933361) | Cantonal Hospital of St. Gallen | 2009-06-01 |
| Safety Study of FLP Injection to Treat Tumor Patients (NCT01361529) | Acea Bio (Hangzhou) Co., Ltd. | 2009-06-01 |
| STAT3 Inhibitor for Solid Tumors (NCT00955812) | M.D. Anderson Cancer Center | 2009-06-01 |
| Study of Erlotinib in Combination With Bortezomib (NCT00895687) | M.D. Anderson Cancer Center | 2009-04-01 |
| Caregiver Assessments of the Quality of Home Hospice Care (NCT00895024) | M.D. Anderson Cancer Center | 2009-04-01 |
| Using Videos in Advance Care Planning for Patients With Advanced Cancer (NCT01241929) | Massachusetts General Hospital | 2009-04-01 |
| Study of Erlotinib in Combination With Dasatinib (NCT00895128) | M.D. Anderson Cancer Center | 2009-04-01 |
| Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: A Qualitative Study (NCT00878267) | M.D. Anderson Cancer Center | 2009-03-01 |
| Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017 (NCT00881569) | Daiichi Sankyo | 2009-03-01 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer (NCT00862524) | Array BioPharma | 2009-03-01 |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (NCT00798252) | Bristol-Myers Squibb | 2009-03-01 |
| Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors (NCT00698841) | Eli Lilly and Company | 2009-02-01 |
| Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow (NCT01567345) | Institut Cancerologie de l'Ouest | 2009-01-14 |
| A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer (NCT00833326) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2009-01-01 |
| A Study of LY2584702 in Participants With Advanced Cancer (NCT01394003) | Eli Lilly and Company | 2008-11-01 |
| Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight (NCT00832520) | New Mexico Cancer Research Alliance | 2008-11-01 |
| RDEA119 and Sorafenib Combination Dose Escalation Study (NCT00785226) | Bayer | 2008-11-01 |
| Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors (NCT00729833) | Pfizer | 2008-09-01 |
| Study of Temsirolimus, Topotecan, and Bortezomib (NCT00770731) | M.D. Anderson Cancer Center | 2008-09-01 |
| Intrapleural Catheter Daily Versus Three Times a Week Drainage (NCT00761618) | M.D. Anderson Cancer Center | 2008-08-22 |
| Doxil, Bevacizumab and Temsirolimus Trial (NCT00761644) | M.D. Anderson Cancer Center | 2008-08-21 |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (NCT00741403) | Cornerstone Pharmaceuticals | 2008-08-01 |
| Safety Study of FP-1039 To Treat Cancer (NCT00687505) | Five Prime Therapeutics, Inc. | 2008-07-01 |
| A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer (NCT00710736) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2008-06-01 |
| A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer (NCT00736372) | Cascadian Therapeutics Inc. | 2008-06-01 |
| Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (NCT00697632) | Mirati Therapeutics Inc. | 2008-06-01 |
| Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy (NCT00688038) | M.D. Anderson Cancer Center | 2008-05-13 |
| A Dose-Escalation Study for Patients With Advanced Cancer (NCT01214642) | Eli Lilly and Company | 2008-05-01 |
| Intervention Toward Truth-Telling and Advanced Directives in the Patient With Advanced or Metastatic Disease (NCT00792896) | National Taiwan University Hospital | 2008-05-01 |
| Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain (NCT00684242) | M.D. Anderson Cancer Center | 2008-05-01 |
| A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer (NCT00664170) | Mast Therapeutics, Inc. | 2008-04-01 |
| Rapamycin Plus Bevacizumab in Advanced Cancers (NCT00667485) | University of Chicago | 2008-04-01 |
| A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer (NCT00658671) | CASI pharmaceuticals, Inc. | 2008-04-01 |
| Study of Oral Palifosfamide Tris in Solid Tumors (NCT00607711) | Alaunos Therapeutics | 2008-03-01 |
| Aggressiveness of Care at the End of Life in Cancer Patients (NCT00980122) | National University Hospital, Singapore | 2008-03-01 |
| Patient and Family Decision Making in the Palliative Care Setting (NCT00682994) | M.D. Anderson Cancer Center | 2008-03-01 |
| Phase 1 Study of MKC-1 in Patients With Advanced Cancer (NCT00656461) | CASI pharmaceuticals, Inc. | 2008-03-01 |
| Spirituality/Religiosity in Patients and Caregivers (NCT00634257) | M.D. Anderson Cancer Center | 2008-02-22 |
| A Study of ARRY-334543 in Patients With Advanced Cancer (NCT00637702) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2008-02-01 |
| Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain (NCT00634010) | M.D. Anderson Cancer Center | 2008-02-01 |
| Multimodal Treatment Strategy for Cancer Cachexia (NCT00625742) | M.D. Anderson Cancer Center | 2008-02-01 |
| Bevacizumab and Temsirolimus in Patients With Advanced Malignancy (NCT00610493) | M.D. Anderson Cancer Center | 2008-01-25 |
| Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours (NCT00621725) | AstraZeneca | 2008-01-01 |
| Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors (NCT00607399) | SGX Pharmaceuticals, Inc. | 2008-01-01 |
| Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors (NCT00606879) | SGX Pharmaceuticals, Inc. | 2008-01-01 |
| A Dose-Escalation Study in Participants With Advanced Cancer (NCT01524224) | Eli Lilly and Company | 2008-01-01 |